企業プロフィール
Prothena 株価・ニュース・カタリスト
- ティッカー:
- PRTA
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- Ireland
株価パフォーマンス
9.39 USD (-0.63%)
終値
最終更新: 2026年8月24日
481M USD
時価総額
株価変動の要因
As of Aug 24, 2026, PRTA closed down 0.63% at $9.39. No new same-company headline was identified in the current news window.
企業概要
事業概要
Prothena is a neuroscience and protein-dysregulation biotechnology company focused on rare neurodegenerative and amyloid-related diseases. Its pipeline is aimed at high-unmet-need areas where clinical data can quickly change the market’s view.
所在地とセクター分類
Headquartered in Ireland and listed on NASDAQ, Prothena has a transatlantic biotech profile. It sits in neuroscience and protein-misfolding biology.
ビジネスモデルの特徴
The company’s value is driven by clinical readouts, partnership activity, and the ability to translate deep biology into differentiated programs. Investors watch safety, efficacy, and the durability of its lead scientific hypotheses.
バイオ業界での位置付け
Prothena sits in the high-risk, high-catalyst neuroscience niche of biotech. The stock can move sharply around data because the programs are small in number but potentially large in impact.
今後のカタリスト
- Prothena's catalysts are PRX012 and the tau/amyloid program cadence, with any next clinical update helping decide whether the neuroscience story still has real optionality. The market wants human data that can support a longer development path rather than another broad platform pitch.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。